Retatrutide
FDA says retatrutide is not a component of an approved drug and cannot be used in compounding under federal law.
Research is not approval.
FDA states on its GLP-1 safety page that retatrutide cannot be used in compounding under federal law. The agency says it is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
FDA describes warnings to telehealth marketers, ingredient distributors and outsourcing facilities over unapproved retatrutide products. A research label, trial announcement or seller claim does not change that regulatory status.
This page does not interpret experimental trial results as established care. It offers no dose, injection instructions or buying links. The source status was checked October 8, 2026 and should be checked again when regulatory information changes.
Original source: Retatrutide ↗
Interpretation is limited to the source linked above. Independent medical review pending.